Barclays analyst Steve Valiquette lowered the firm’s price target on Molina Healthcare to $375 from $400 and keeps an Overweight rating on the shares. The company’s reduced membership allocations will lead to a $1.5B premium revenue guidance cut for 2024, Valiquette tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MOH:
- Molina Healthcare to double California revenue with Medi-Cal contracts in 2024
- Molina Healthcare to record $200M impairment charge in Q4 on leased space
- Molina Healthcare upgraded to Neutral at BofA on ‘high confidence’ in EPS growth
- Molina Healthcare upgraded to Neutral from Underperform at BofA
- Managed care company returns will be tough to keep replicating, WSJ says
